

Henriette de Loor

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9298563/henriette-de-loor-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46
papers

1,692
citations

24
h-index

41
g-index

49
ext. papers

1,971
ext. citations

4.7
avg, IF

4.34
L-index

#	Paper	IF	Citations
46	Contemporary kidney transplantation has a limited impact on bone microarchitecture.. <i>Bone Reports</i> , 2022 , 16, 101172	2.6	0
45	On Methods for the Measurement of the Apelin Receptor Ligand Apelin.. <i>Scientific Reports</i> , 2022 , 12, 7763	4.9	0
44	Changes in kynurenine pathway metabolites after acute psychosocial stress in healthy males: a single-arm pilot study. <i>Stress</i> , 2021 , 1-11	3	1
43	Effect of Dietary Inulin Supplementation on the Gut Microbiota Composition and Derived Metabolites of Individuals Undergoing Hemodialysis: A Pilot Study. <i>Journal of Renal Nutrition</i> , 2021 , 31, 512-522	3	5
42	Determination of tacrolimus, three mono-demethylated metabolites and a M1 tautomer in human whole blood by liquid chromatography - tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021 , 205, 114296	3.5	0
41	Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug-Bug Interaction?. <i>Toxins</i> , 2020 , 12,	4.9	9
40	The renal transport of hippurate and protein-bound solutes. <i>Physiological Reports</i> , 2020 , 8, e14349	2.6	3
39	Cognitive Function and Uremic Toxins after Kidney Transplantation: An Exploratory Study.. <i>Kidney360</i> , 2020 , 1, 1398-1406	1.8	5
38	Spot urine versus 24-hour urine collection for estimation of the generation of uremic toxins originating from gut microbial metabolism. <i>Kidney International</i> , 2020 , 98, 782-784	9.9	1
37	In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019 , 124, 50-55	3.1	2
36	Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation. <i>Kidney International</i> , 2019 , 95, 188-198	9.9	62
35	Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 1507-1513	4	10
34	Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 989-996	6.1	7
33	Exploring binding characteristics and the related competition of different protein-bound uremic toxins. <i>Biochimie</i> , 2017 , 139, 20-26	4.6	19
32	Comparative performance of oral midazolam clearance and plasma 4-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 1539-1549	3.8	20
31	The influence of renal transplantation on retained microbial-human co-metabolites. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 1721-1729	4.3	27
30	The Influence of Prebiotic Arabinosyl Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2016 , 11, e0153893	3.7	61

29	A liquid chromatography - tandem mass spectrometry method to measure a selected panel of uremic retention solutes derived from endogenous and colonic microbial metabolism. <i>Analytica Chimica Acta</i> , 2016 , 936, 149-56	6.6	27
28	Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 3479-3487	12.7	83
27	Metabolism, Protein Binding, and Renal Clearance of Microbiota-Derived p-Cresol in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 1136-44	6.9	43
26	Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 1151-60	6.2	10
25	Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 548-59	3.8	39
24	Response to Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid dose. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1473-4	3.8	1
23	The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. <i>Pharmacogenomics Journal</i> , 2015 , 15, 144-52	3.5	33
22	FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α -synuclein-based rat model for Parkinson's disease. <i>Neurobiology of Aging</i> , 2015 , 36, 1559-68	5.6	60
21	The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells. <i>Molecular Pharmaceutics</i> , 2015 , 12, 758-68	5.6	22
20	Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 1965-72	4.3	8
19	Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis. <i>Journal of Pharmaceutical Sciences</i> , 2014 , 103, 2565-70	3.9	24
18	Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 6782-9	5.9	34
17	Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 597-606	1.9	33
16	Albumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfate. <i>Biopharmaceutics and Drug Disposition</i> , 2013 , 34, 165-75	1.7	79
15	Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism. <i>Pharmacogenomics</i> , 2013 , 14, 1467-80	2.6	26
14	In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 92, 366-75	6.1	83
13	In Vivo CYP3A4-Activity, CYP3A5-Genotype and Hematocrit Predict Tacrolimus Dose-Requirements and Clearance in Renal Transplant Recipients. <i>Transplantation</i> , 2012 , 94, 248-249	1.8	
12	A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1-hydroxymidazolam and 4-hydroxymidazolam in human plasma. <i>Biomedical Chromatography</i> , 2011 , 25, 1091-8	1.7	17

11	In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 90, 414-22	6.1	32
10	p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 1182-9	6.9	217
9	Apparent elevation of cyclosporine whole blood concentrations in a renal allograft recipient. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 529-31	3.2	13
8	p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009 , 4, 1932-8	6.9	119
7	Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. <i>Journal of Chromatography A</i> , 2009 , 1216, 4684-8	4.5	54
6	Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology. <i>Clinica Chimica Acta</i> , 2008 , 389, 87-92	6.2	30
5	Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. <i>Clinical Therapeutics</i> , 2008 , 30, 673-83	3.5	91
4	Does the biomarker 15N-lactose ureide allow to estimate the site of fermentation of resistant starch?. <i>European Journal of Nutrition</i> , 2008 , 47, 217-23	5.2	6
3	The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. <i>Transplantation</i> , 2007 , 84, 362-73	1.8	47
2	p-Cresol for better or worse: but what are we measuring?. <i>Kidney International</i> , 2006 , 70, 232; author reply 232-3	9.9	7
1	Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. <i>Clinical Chemistry</i> , 2005 , 51, 1535-8	5.5	145